<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33792444</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5-6</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Novel serum autoantibodies against &#xdf;-actin (ACTB) in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>388</StartPage><EndPage>394</EndPage><MedlinePgn>388-394</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.1885448</ELocationID><Abstract><AbstractText>To identify novel biomarkers using the serological analysis of recombinant cDNA expression libraries (SEREX) method and to evaluate their clinical significance in amyotrophic lateral sclerosis (ALS). Serum of ALS patients were screened for autoantibodies using the SEREX method. The identified autoantibodies were validated by measuring their serum levels in 70 ALS patients, 60 normal controls (NC), and 62 Parkinson disease (PD) patients using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA). The clinical relevance of these autoantibodies was investigated in ALS patients. SEREX identified 16 candidate antigens including &#x3b2;-actin (ACTB) in addition to proteasome subunit alpha type 7 (PSMA7) that we previously reported, and serum levels of antibodies against ACTB, were significantly higher in ALS patients than in NC (<i>p</i>&#x2009;&lt;&#x2009;0.001) and PD patients (<i>p</i>&#x2009;=&#x2009;0.001). Moreover, serum levels of anti-ACTB antibody were higher in advanced stage ALS patients (Stage 4 on the King's ALS clinical staging) and in those with more severe disability (ALS Functional Rating Scale revised [ALSFRS-R] score &lt; 40.5) compared to early stage (Stage 2 [2nd region involved)]) patients and those with less severe disability (ALSFRS-R score &#x2265; 40.5) (<i>p</i>&#x2009;=&#x2009;0.003, <i>p</i>&#x2009;=&#x2009;0.014). Anti-ACTB antibody levels were also negatively correlated with ALSFRS-R score (&#x3c1; = -0.409, <i>p</i>&#x2009;=&#x2009;0.001), but positively correlated with clinical disease stage (&#x3c1;&#x2009;=&#x2009;0.355, <i>p</i>&#x2009;=&#x2009;0.003), and showed a weak positive correlation with disease duration (&#x3c1;&#x2009;=&#x2009;0.294, <i>p</i>&#x2009;=&#x2009;0.014). Anti-ACTB antibodies may be a potential biomarker of ALS could indicate disease severity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sugimoto</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Dongzhimen Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8767-255X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibuya</LastName><ForeName>Kazutomo</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4061-0412</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isose</LastName><ForeName>Sagiri</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Chibahigashi National Hospital, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koide</LastName><ForeName>Mizuho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Chibahigashi National Hospital, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiwasa</LastName><ForeName>Takaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuwabara</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4716-8578</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000199">Actins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000199" MajorTopicYN="Y">Actins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACTB</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">autoantibody</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>1</Day><Hour>12</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33792444</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.1885448</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>